相似文献
1
Conversion of the potent delta-opioid agonist H-Dmt-Tic-NH-CH(2)-bid into delta-opioid antagonists by N(1)-benzimidazole alkylation(1).
J Med Chem. 2005 Dec 29;48(26):8112-4. doi: 10.1021/jm058259l.
2
Evaluation of the Dmt-Tic pharmacophore: conversion of a potent delta-opioid receptor antagonist into a potent delta agonist and ligands with mixed properties.
J Med Chem. 2002 Jan 31;45(3):713-20. doi: 10.1021/jm010449i.
3
Further studies on the Dmt-Tic pharmacophore: hydrophobic substituents at the C-terminus endow delta antagonists to manifest mu agonism or mu antagonism.
J Med Chem. 1999 Dec 2;42(24):5010-9. doi: 10.1021/jm990165m.
4
Potent delta-opioid receptor agonists containing the Dmt-Tic pharmacophore.
J Med Chem. 2002 Dec 5;45(25):5556-63. doi: 10.1021/jm020336e.
5
Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore.
J Med Chem. 2006 Sep 7;49(18):5610-7. doi: 10.1021/jm060741w.
6
Direct influence of C-terminally substituted amino acids in the Dmt-Tic pharmacophore on delta-opioid receptor selectivity and antagonism.
J Med Chem. 2004 Jul 29;47(16):4066-71. doi: 10.1021/jm040033f.
7
Synthesis and opioid activity of N,N-dimethyl-Dmt-Tic-NH-CH(R)-R' analogues: acquisition of potent delta antagonism.
Bioorg Med Chem. 2003 Dec 1;11(24):5435-41. doi: 10.1016/j.bmc.2003.09.039.
8
Evolution of the Dmt-Tic pharmacophore: N-terminal methylated derivatives with extraordinary delta opioid antagonist activity.
J Med Chem. 1997 Sep 12;40(19):3100-8. doi: 10.1021/jm9607663.
9
Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists.
J Med Chem. 2005 Dec 15;48(25):8035-44. doi: 10.1021/jm050377l.
10
Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic.
J Med Chem. 2008 Aug 28;51(16):5109-17. doi: 10.1021/jm800587e. Epub 2008 Aug 5.
引用本文的文献
1
Development and characterisation of novel fentanyl-delta opioid receptor antagonist based bivalent ligands.
Br J Anaesth. 2015 Apr;114(4):646-56. doi: 10.1093/bja/aeu454. Epub 2015 Feb 13.
2
Chiral Effect of a Phe Residue in Position 3 of the Dmt-L(or D)-Tic Analogues on Opioid Functional Activities.
ACS Med Chem Lett. 2013 Jul 11;4(7):656-659. doi: 10.1021/ml400115n.
3
Ligands raise the constraint that limits constitutive activation in G protein-coupled opioid receptors.
J Biol Chem. 2013 Aug 16;288(33):23964-78. doi: 10.1074/jbc.M113.474452. Epub 2013 Jul 8.
4
Role of 2',6'-dimethyl-l-tyrosine (Dmt) in some opioid lead compounds.
Bioorg Med Chem. 2010 Aug 15;18(16):6024-30. doi: 10.1016/j.bmc.2010.06.073. Epub 2010 Jun 25.
5
Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic.
J Med Chem. 2008 Aug 28;51(16):5109-17. doi: 10.1021/jm800587e. Epub 2008 Aug 5.
6
Synthesis and in vitro evaluation of a library of modified endomorphin 1 peptides.
Bioorg Med Chem. 2008 Jun 1;16(11):6286-96. doi: 10.1016/j.bmc.2008.04.020. Epub 2008 Apr 15.
7
Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mixed mu-agonist/delta-antagonist and dual mu-agonist/delta-agonist opioid ligands.
J Med Chem. 2007 Jun 14;50(12):2753-66. doi: 10.1021/jm061238m. Epub 2007 May 12.
8
New opioid designed multiple ligand from Dmt-Tic and morphinan pharmacophores.
J Med Chem. 2006 Sep 7;49(18):5640-3. doi: 10.1021/jm0605785.
9
Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore.
J Med Chem. 2006 Sep 7;49(18):5610-7. doi: 10.1021/jm060741w.
10
New 2',6'-dimethyl-L-tyrosine (Dmt) opioid peptidomimetics based on the Aba-Gly scaffold. Development of unique mu-opioid receptor ligands.
J Med Chem. 2006 Jun 29;49(13):3990-3. doi: 10.1021/jm0603264.
本文引用的文献
1
A new structural motif for mu-opioid antagonists.
J Med Chem. 2005 May 19;48(10):3644-8. doi: 10.1021/jm0491795.
2
Development of potent mu-opioid receptor ligands using unique tyrosine analogues of endomorphin-2.
J Med Chem. 2005 Jan 27;48(2):586-92. doi: 10.1021/jm049384k.
3
Direct influence of C-terminally substituted amino acids in the Dmt-Tic pharmacophore on delta-opioid receptor selectivity and antagonism.
J Med Chem. 2004 Jul 29;47(16):4066-71. doi: 10.1021/jm040033f.
4
Development of potent bifunctional endomorphin-2 analogues with mixed mu-/delta-opioid agonist and delta-opioid antagonist properties.
J Med Chem. 2004 Jul 1;47(14):3591-9. doi: 10.1021/jm030649p.
5
Dmt and opioid peptides: a potent alliance.
Biopolymers. 2003;71(2):86-102. doi: 10.1002/bip.10399.
6
Potent delta-opioid receptor agonists containing the Dmt-Tic pharmacophore.
J Med Chem. 2002 Dec 5;45(25):5556-63. doi: 10.1021/jm020336e.
7
Evaluation of the Dmt-Tic pharmacophore: conversion of a potent delta-opioid receptor antagonist into a potent delta agonist and ligands with mixed properties.
J Med Chem. 2002 Jan 31;45(3):713-20. doi: 10.1021/jm010449i.
8
From models to molecules: opioid receptor dimers, bivalent ligands, and selective opioid receptor probes.
J Med Chem. 2001 Jul 5;44(14):2259-69. doi: 10.1021/jm010158+.
9
N-Cyclohexylethyl-N-noroxymorphindole: a mu-opioid preferring analogue of naltrindole.
Bioorg Med Chem Lett. 2000 Nov 6;10(21):2449-51. doi: 10.1016/s0960-894x(00)00479-0.
10
Further studies on the Dmt-Tic pharmacophore: hydrophobic substituents at the C-terminus endow delta antagonists to manifest mu agonism or mu antagonism.
J Med Chem. 1999 Dec 2;42(24):5010-9. doi: 10.1021/jm990165m.
Zotero 插件